NoblePath CRO

We are a Turkey-based clinical research organisation committed to innovation, patient safety, and scientific integrity. We partner with international pharmaceutical and biotech companies to deliver high-quality, ethical, and efficient clinical research in Turkey - not just as a CRO, but as a true strategic partner.

Founded by a Clinical Nurse and Health Lawyer with 13 years of oncology intensive care experience, NoblePath exists to give international sponsors access to Turkey's exceptional clinical trial capabilities - without compromising on the standards that protect patients and data.

─────

What we do:

· Phase I and II clinical trials across oncology, rare disease, neurology, immunology, and metabolic disorders

· Full TITCK regulatory strategy and submission management for international sponsors

· ICH E6(R2) compliant trial operations — audit-ready from day one

· Supporting early-phase and complex clinical programs across all therapeutic areas

· Site selection, qualification, and management across Turkey

· Patient recruitment and retention built for protocol fit, not just speed

─────

Why Turkey:

Turkey ranked 26th globally for clinical trial volume (EFPIA, 2020).

Large oncology and rare disease patient populations — with a high proportion of treatment-naïve patients.

TITCK operates a structured, internationally aligned regulatory framework.

Ethics committees and regulatory submissions run in parallel — saving weeks on start-up.

The sponsors who discover Turkey early gain a recruiting and timeline advantage that compounds.

─────

What makes NoblePath different:

We are an ethics-first , founder-led CRO whose expertise in clinical research regulations, drug development processes, and healthcare compliance is not just an ethical foundation - it is a direct operational advantage for every sponsor who partners with NoblePath.

Our vision extends beyond operations: to position NoblePath as a trusted CRO partner and a future hub for clinical research education